Diagnostic performance of non-invasive markers for the presence of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome

2017 ◽  
Author(s):  
Evangeline Vassilatou ◽  
Sophia Lafoyianni ◽  
Dimitra-Argyro Vassiliadi ◽  
Dimitrios Ioannidis ◽  
Stavroula Paschou ◽  
...  
Keyword(s):  
Liver Disease ◽  
Polycystic Ovary Syndrome ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Diagnostic Performance ◽  
Polycystic Ovary ◽  
Premenopausal Women ◽  
Ovary Syndrome ◽  
Nonalcoholic Fatty Liver ◽  
Non Invasive

scholarly journals Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease

2015 ◽  
Vol 173 (6) ◽  
pp. 739-747 ◽  
Author(s):  
E Vassilatou ◽  
D A Vassiliadi ◽  
K Salambasis ◽  
H Lazaridou ◽  
N Koutsomitopoulos ◽  
...  
Keyword(s):  
Liver Disease ◽  
Polycystic Ovary Syndrome ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Polycystic Ovary ◽  
Premenopausal Women ◽  
Model Assessment ◽  
Ovary Syndrome ◽  
Nonalcoholic Fatty Liver

ObjectiveLimited data exist concerning the presence of polycystic ovary syndrome (PCOS) in premenopausal women with nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the prevalence of PCOS in overweight and obese premenopausal women with NAFLD.DesignProspective, observational, and cross-sectional study.MethodsWe studied 110 apparently healthy, overweight, and obese (BMI: 25.1–49.1 kg/m2) premenopausal women (age: 18–45 years) reporting no or minimal alcohol consumption for NAFLD with abdominal ultrasonography after excluding causes of secondary liver disease and for PCOS (Rotterdam criteria) with clinical examination, biochemical evaluation, and pelvic ultrasonography. Insulin resistance (IR) was assessed by homeostasis model assessment of IR (HOMA-IR), and free androgen index was calculated.ResultsNAFLD was detected in 71/110 women (64.5%). Women with NAFLD compared to women without NAFLD were more commonly diagnosed with PCOS (43.7% vs 23.1%, respectively,P=0.04), metabolic syndrome (30.2% vs 5.3%, respectively,P=0.003), and abnormal lipid profile (81.1% vs 51.3%,P=0.002). All women with abnormal glucose metabolism had NAFLD (P=0.01). Although PCOS was associated with NAFLD (OR 2.6, 95% CI: 1.1–6.2,P=0.04), in a multivariate analysis higher HOMA-IR values (OR 2.2, 95% CI: 1.1–4.4,P=0.02) and triglyceride levels (OR 1.01, 95% CI: 1.00–1.02,P=0.04) independently predicted NAFLD, after adjusting for age, BMI, and waist-to-hip ratio.ConclusionsThese findings indicate an increased prevalence of PCOS in overweight and obese premenopausal women with NAFLD, although it is not supported that the syndrome is primarily involved in NAFLD. Evaluation for PCOS may be considered in these women.

Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome

Maturitas ◽  
2018 ◽  
Vol 116 ◽  
pp. 1-7 ◽  
Author(s):  
Evangeline Vassilatou ◽  
Sophia Lafoyianni ◽  
Dimitra Argyro Vassiliadi ◽  
Dimitrios Ioannidis ◽  
Stavroula A. Paschou ◽  
...  
Keyword(s):  
Liver Disease ◽  
Polycystic Ovary Syndrome ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Polycystic Ovary ◽  
Premenopausal Women ◽  
Visceral Adiposity Index ◽  
Ovary Syndrome ◽  
Nonalcoholic Fatty Liver

A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease

2013 ◽  
Vol 80 (6) ◽  
pp. 843-849 ◽  
Author(s):  
Alison J. Dawson ◽  
Thozhukat Sathyapalan ◽  
Jacqueline A. J. Smithson ◽  
Rebecca V. Vince ◽  
Anne-Marie Coady ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Liver Disease ◽  
Polycystic Ovary Syndrome ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Nonalcoholic Fatty Liver ◽  
Risk Indices

scholarly journals MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease

2017 ◽  
Vol 177 (3) ◽  
pp. R145-R158 ◽  
Author(s):  
Djuro Macut ◽  
Ivana Božić-Antić ◽  
Jelica Bjekić-Macut ◽  
Konstantinos Tziomalos
Keyword(s):  
Liver Disease ◽  
Polycystic Ovary Syndrome ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Liver Damage ◽  
Fatty Liver Disease ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Endocrine Disease ◽  
Nonalcoholic Fatty Liver

Polycystic ovary syndrome (PCOS) is a frequent endocrine disease in women, with a number of metabolic and reproductive consequences. Obesity, insulin resistance (IR) and type 2 diabetes are prominent metabolic characteristics of PCOS and common factors affecting liver function and generating nonalcoholic fatty liver disease (NAFLD). Multiple genes involved in the synthesis of androgens, cytokines and IR, as well as acquired factors, such as endocrine disruptors, could associate the etiopathogenesis of PCOS and NAFLD. Besides the high prevalence of PCOS in general population, NAFLD was shown to be a frequent condition in transition periods, such as adolescence and menopause. Although liver biopsy is considered to be the gold standard for diagnosing liver damage, its routine use in such a prevalent condition as PCOS can be related to a higher rate of complications. Therefore, it is necessary to be able to diagnose NAFLD using simple and reliable surrogate markers. Recently, fatty liver index and NAFLD fatty liver score analyzed in large cohorts of PCOS women have been shown as accurate markers of liver damage in this metabolically vulnerable population. Lifestyle changes are still the mainstay of the management of NAFLD in PCOS, although prospective randomized controlled clinical studies remain a priority in the field. With regard to medications, metformin may be the drug of choice for treating PCOS patients with NAFLD when pharmacologic therapy is considered. Liraglutide use in obese PCOS has shown favorable effects on the predictors of liver fibrosis. In this review, we aim to summarize the influence of the common risk factors and to discuss the diagnostic approaches and management options for NAFLD in patients with PCOS.

Sign in / Sign up

Export Citation Format

Share Document